Asian Spectator


The Times

.

News Lounge Comes to Türkiye, Fostering Dialogue Across Borders

ANTALYA, TURKEY – Media OutReach Newswire – 14 November 2026 – News Lounge, the flagship program of China News Service, welcomed its first group of international guests since its ov...

The European Art of Taste: The Assurances And Safeness Of Ital...

BOLOGNA, Italy, July 30 2020 /PRNewswire-AsiaNet/ -- The European Art of Taste – Italian Fruit & Veg Masterpieces, despite the delay brought by the Covid-19 emergency, is preparing...

TEEN REGIME: A Story of Generational Conflict, AI Tech and Hope

TOKYO, JAPAN - Media OutReach - 9 September 2022 - NHK WORLD-JAPAN presents TEEN REGIME, an all-new dramatic sci-fi miniseries. The first three episodes are currently available with Englis...

UnionPay Acceptance Network Expands to 180 Countries and Regions

SHANGHAI, March 19, 2021 /PRNewswire-AsiaNet/ -- UnionPay International (UPI) announced today that with significant progress in Latin America, UnionPay acceptance network has now extended to...

Stylish Gen Z smartphone TECNO CAMON19 with 64 MP camera, RGBW sensor set to mark its debut in India in Mid-July

NEWDELHI, INDIA - Media OutReach - 7 July 2022 - The blockbusting CAMON19 of TECNO is to debut in India on July 12 – a product combining fashion aesthetics with cool technology. TECNO...

Xi'an sets up the "Mayor's Special Award" to encourage innovat...

XI'AN, China, Aug. 10, 2020 /Xinhua-AsiaNet/ -- On August 5, the award ceremony of the "Mayor's Special Award" that is designed to recognize outstanding contributions to the development of X...

Hang Lung Wins String of Awards for its Environmental, Social and Governance Achievements

HONG KONG SAR - Media OutReach - 6 January 2022 - Hang Lung Group Limited (Stock Code: 00010) and Hang Lung Properties Limited (Stock Code: 00101) (collectively, "the Companie...

Gem Sri Lanka 2026 Concludes Successfully: Platinum Sponsor GUILD Propels Industry Growth

Colombo, Sri Lanka - Media OutReach Newswire - 12 January 2026 - From January 7 to 9, Gem Sri Lanka 2026 was successfully held at the Shangri-La Hotel in the heart of Colombo, the capital o...

Hagleitner Hygiene International - World first in hygiene: Touch-free wet wipe dispensing machine

Creators expect it to be a game changer for wet wipesFRANKFURT AM MAIN, GERMANY - Newsaktuell - 12 October 2022 - This advance in technology was actually overdue, explains hygiene pioneer Ha...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalmarsbahisuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet resmi girişStreamEastStreamEast